Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal Pigment Epithelial Detachment changes in Age-related Macular Degeneration treated with Aflibercept, Ranibizumab and Bevacizumab
TCTR20161007004Phase 4Recruiting
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Oct 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept, ranibizumab, bevacizumab in age-related macular degeneration (AMD), sponsored by Faculty of Medicine, Chulalongkorn University. Started Oct 2016; status: recruiting.
02
Drugs
afliberceptranibizumabbevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on TCTR20161007004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20161007004.